Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx1 RVF in Healthy Volunteers
NCT04754776Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jun 2021
- Primary completion
- Apr 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAdOx1 RVF in Rift Valley fever (RVF) (3 arms), sponsored by University of Oxford. Primary endpoints: Local reactogenicity at 7 days, Systemic reactogenicity at 7 days and 3 more. Started Jun 2021; status: completed.
02
Drugs
ChAdOx1 RVF
03
Conditions
Rift Valley fever (RVF)
Beyond the preview
Go deeper on NCT04754776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04754776.